Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report

Abstract

Enterococcus faecium ( E. faecium ) is one of the core components of enterococci and causes serious illnesses in the elderly and immunocompromised patients. Due to its adaptive traits and antibiotic resistance, E. faecium has evolved as a worldwide hospital-associated pathogen, especially vancomsycin-resistant Enterococcus faecium (VREfm). Pneumonia caused by VREfm is quite rare in clinical settings, and optimal treatment has not yet been determined. Here, we present a case of nosocomial VREfm pneumonia with lung cavitation following adenovirus infection, which was successfully treated with linezolid and contezolid.

Contezolid Use for Treating Vancomycin-Resistant Enterococcus Biliary Tract Infections in a Centenarian Patient: A Case Report

“…Reports suggest that the treatment is effective in elderly patients and those with compromised hepatic or renal function at half the standard dose [16,18]. A 4-month application of contezolid in an elderly patient with VRE-induced pneumonia showed no evident side effects [21]. Our similar case demonstrated prompt infection control and overall systemic condition correction following therapeutic experiences.…”

Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid

“…In addition, our case is the first clinical evidence to demonstrate the efficacy and safety of long-term use of contezolid. This case has been on contezolid for eight months, and the longest reported case of contezolid use in the available published literature is a 101-year-old male patient with nosocomial vancomsycin-resistant Enterococcus faecium pneumonia who received contezolid for nearly four consecutive months, resulting in the disappearance of lesions, which may also suggest that contezolid has a good efficacy and safety profile in relevant infectious diseases ( 19 ). Our case may be helpful to provide a reference for further studies in the field of anti-TB treatment.…”

Compassionate use of contezolid in a toddler with severe community-acquired pneumonia induced by staphylococcus aureus: a case report and follow-up

“…Conteziold, an orally administered oxazolidinone antibiotic, gained approval from the National Medical Products Administration (NMPA) of China in June 2021 for managing complicated skin and soft tissue infections (cSSTI) caused by SA, streptococcus pyogenes, or streptococcus agalactis (17). Owing to its enhanced safety profile and ongoing clinical progress, the scope of contezolid's clinical application continues to expand, benefiting a growing number of patients with Gram-positive bacterial infections (18)(19)(20)(21).…”